

AMENDMENT

IN THE CLAIMS:

Please amend the claims as follows:

1-3. (Canceled).

4. (Previously amended) A microfluidized lysate preparation free of dextran made by microfluidizing a slurry of at least one *Leishmania* parasite strain through a chamber and disrupting the leishmania parasite strain with a sudden release of pressure.

5-10. (Canceled).

11. (Original) A kit comprising the microfluidized lysate preparation of claim 4 and directions for determining whether a subject has been exposed to a *Leishmania* parasite or was afflicted with Leishmaniasis.

12. (Previously amended) The kit of claim 11, wherein the *Leishmania* parasite strain is *L. tropica*, *L. mexicana*, *L. guyanensis*, *L. braziliensis*, *L. major*, *L. donovani*, *L. chagasi*, *L. amazonensis*, *L. peruviana*, *L. panamensis*, *L. pifanoi*, *L. infantum*, or *L. aethiopica*.

13-21. (Canceled).

22. (Previously amended) The microfluidized lysate preparation of claim 4, and further comprising a pharmaceutically acceptable stabilizer.

23. (Previously amended) The microfluidized lysate preparation of claim 22, wherein the pharmaceutically acceptable stabilizer is phenol.

24. (Previously amended) The microfluidized lysate preparation of claim 22, wherein the composition is in the form of a liquid.

25. (Previously amended) The microfluidized lysate preparation of claim 22, wherein the composition may be frozen or freeze-dried.

26-28. (Canceled).

29. (Previously added) The microfluidized lysate preparation of claim 4, wherein the microfluidized lysate preparation is heat treated.

30. (Previously amended) The microfluidized lysate preparation of claim 4, wherein the *Leishmania* parasite strain is *L. tropica*, *L. mexicana*, *L. guyanensis*, *L. braziliensis*, *L. major*, *L. donovani*, *L. chagasi*, *L. amazonensis*, *L. peruviana*, *L. panamensis*, *L. pifanoi*, *L. infantum*, or *L. aethiopica*.

31. (Previously added) An immunogenic composition comprising the microfluidized lysate preparation of claim 4.